Attempted suicide with the SGLT2 inhibitor empagliflozin saves patient's life

被引：1
|
作者：
Schneider, A. [1 ]
Lengenfelder, B. [1 ]
机构：
[1] Univ Klinikum Wurzburg, Med Klin & Poliklin 1, Intens & Notfallmed, Oberdurrbacher Str 6, D-97080 Wurzburg, Germany
来源：
DIABETOLOGE | 2018年 / 14卷 / 02期
关键词：
SGLT2; inhibitors; Empagliflozin; Suicide attempt; Overdose; Hypoglycemia;
D O I：
10.1007/s11428-018-0310-6
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A suicide attempt by a 74-year-old female patient by means of an overdose of the SGLT2 inhibitor empagliflozin is reported. Laboratory tests could not detect any substantial side effects of empagliflozin, such as hypoglycemia or imbalances in the acid-base metabolism. The patient developed ventricular fibrillation in the further course. Short-term resuscitation and defibrillation was necessary, followed by coronary angiography, which revealed three-vessel coronary artery disease. This was treated by PCI and stenting. Afterwards, she was transferred to a rehabilitation centre. Presumably, the failed suicide attempt with empagliflozin ultimately saved the patient's life.
引用
收藏
页码：99 / 100
页数：2
相关论文
共 50 条
  • [1] ADVERTISEMENT Jardiance (SGLT2 inhibitor, Empagliflozin). Indications
    不详
    TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING, 2022, 142 (09) : 756 - 756
  • [2] SGLT2 inhibitor empagliflozin: finally at the latter stage of understanding?
    Chan, Gary C. W.
    Tang, Sydney C. W.
    KIDNEY INTERNATIONAL, 2018, 93 (01) : 22 - 24
  • [3] SGLT2 Inhibitor Empagliflozin Before Coronary Angiography: Can We Reduce Patient Stress?
    Lukenda, Katica Cvitkusic
    Gasparovic, Ana Cipak
    Milic, Mirta
    Radovani, Barbara
    Jakab, Jelena
    Kovacevic, Ana
    Gudelj, Ivan
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 84 (18) : B70 - B71
  • [4] THE SGLT2 INHIBITOR EMPAGLIFLOZIN DOES NOT EXHIBIT PRO THROMBOTIC EFFECTS
    Santos-Gallego, Carlos G.
    Zafar, Mohammad
    Antonio, Rodolfo San
    Ibanez, Juan Antonio Requena
    Botifa, Maria Belen Picatoste
    Ishikawa, Kiyotake
    Watanabe, Shin
    Hajjar, Roger
    Fuster, Valentin
    Badimon, Juan
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 1852 - 1852
  • [5] The SGLT2 inhibitor empagliflozin reduces mortality in experimental pulmonary hypertension
    Chowdhury, B.
    Luu, V. Z.
    Luu, A. Z.
    Kabir, M. G.
    Pan, Y.
    Teoh, H.
    Quan, A.
    Mazer, C. D.
    Verma, S.
    EUROPEAN HEART JOURNAL, 2019, 40 : 11 - 11
  • [6] The SGLT2 inhibitor empagliflozin attenuates atherosclerosis progression by inducing autophagy
    Hualin Xu
    Jie Fu
    Qiang Tu
    Qingyun Shuai
    Yizhi Chen
    Fuyun Wu
    Zheng Cao
    Journal of Physiology and Biochemistry, 2024, 80 : 27 - 39
  • [7] The SGLT2 inhibitor Empagliflozin shown to reduce hospitalizations for heart failure
    Idris, Iskandar
    DIABETES OBESITY & METABOLISM, 2016, 18 (01): : 110 - 110
  • [8] Biotransformation and mass balance of the SGLT2 inhibitor empagliflozin in healthy volunteers
    Chen, Lin-Zhi
    Jungnik, Arvid
    Mao, Yanping
    Philip, Elsy
    Sharp, Dale
    Unseld, Anna
    Seman, Leo
    Woerle, Hans-Juergen
    Macha, Sreeraj
    XENOBIOTICA, 2015, 45 (06) : 520 - 529
  • [9] A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans
    Michel, Martin C.
    Mayoux, Eric
    Vallon, Volker
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2015, 388 (08) : 801 - 816
  • [10] A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans
    Martin C. Michel
    Eric Mayoux
    Volker Vallon
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388 : 801 - 816
12345